Spinal Cord Injury
Spinal Cord Injury (SCI) causes extreme back pain and at times triggers an “accelerating aging” in men; although the disease is incurable to date, vigorous developments in the treatment domain are easily evident. Currently, there are more than 40 drugs in the pipeline of SCI treatment. Males are more likely to experience Spinal Cord Injury than females and account for approximately 80% of new SCI cases.
Currently, the treatment therapy includes drugs to reduce symptoms and surgery to stabilize the spine. Learn more about the incurable disease, its symptoms, epidemiological insights, marketed therapies, and treatment modalities through the newsletter. DelveInsight estimates that an increase in incident cases, growing awareness for injuries, and the R&D activities all combined together push the growth of the Spinal Cord Injury therapeutic market.
The newsletter also outlines a complete picture of the Spinal Cord Injury market landscape, pipeline therapies, clinical trials, recent happenings in the SCI market, mergers and collaborations, licensing deals, along with the peak conferences that are expected to occur in the near future.
Gain access to the newsletter by filling up the form to the right.
Subscribe to our newsletter series for deep and rich insights into the pharma and healthcare market. Join our Newsletter series and get rich insights delivered every week.
Stay tuned for more.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- R&D in the field
- Top conferences
- News Flash
- Recent Research Activities
- Market insights
- Support from International organizations
- Collaborations and deals in the domain